- Home
- CRVS vs SKYH Comparison
CRVS vs SKYH Comparison
Compare CRVS & SKYH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- SKYH
- Stock Information
- Founded
- CRVS 2014
- SKYH 2017
- Country
- CRVS United States
- SKYH United States
- Employees
- CRVS N/A
- SKYH N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- SKYH Military/Government/Technical
- Sector
- CRVS Health Care
- SKYH Industrials
- Exchange
- CRVS Nasdaq
- SKYH Nasdaq
- Market Cap
- CRVS 305.4M
- SKYH 325.2M
- IPO Year
- CRVS 2016
- SKYH N/A
- Fundamental
- Price
- CRVS $5.75
- SKYH $10.52
- Analyst Decision
- CRVS Strong Buy
- SKYH Strong Buy
- Analyst Count
- CRVS 4
- SKYH 3
- Target Price
- CRVS $15.00
- SKYH $14.83
- AVG Volume (30 Days)
- CRVS 518.7K
- SKYH 104.9K
- Earning Date
- CRVS 08-07-2025
- SKYH 08-12-2025
- Dividend Yield
- CRVS N/A
- SKYH N/A
- EPS Growth
- CRVS N/A
- SKYH N/A
- EPS
- CRVS N/A
- SKYH N/A
- Revenue
- CRVS N/A
- SKYH $20,919,000.00
- Revenue This Year
- CRVS N/A
- SKYH $124.39
- Revenue Next Year
- CRVS N/A
- SKYH $83.05
- P/E Ratio
- CRVS N/A
- SKYH N/A
- Revenue Growth
- CRVS N/A
- SKYH 94.38
- 52 Week Low
- CRVS $2.54
- SKYH $9.28
- 52 Week High
- CRVS $10.00
- SKYH $14.52
- Technical
- Relative Strength Index (RSI)
- CRVS 65.10
- SKYH 52.98
- Support Level
- CRVS $5.28
- SKYH $10.20
- Resistance Level
- CRVS $5.64
- SKYH $10.89
- Average True Range (ATR)
- CRVS 0.30
- SKYH 0.40
- MACD
- CRVS 0.03
- SKYH 0.02
- Stochastic Oscillator
- CRVS 77.70
- SKYH 46.43
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About SKYH Sky Harbour Group Corporation
Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.